Replies to post #151750 on Biotech Values

[ghmm]

BMRN:

I was a bit nervous with 6MWK based on how Phase 2 6MWK was. I did a quick look and listen of the call given the disease and other ERT should be a clear approval. On a prior call they said 15% of identified patients in North America so x-US clearly key (though obviously some countries look to US approval as proxy).

The PARP and Pompe data are still to come. Both are pretty important in valuation models IMO. The PARP study in solid tumors seems especially promising (from the remarks in blood cancers seems to not be).